title: Hyperphosphatemia and phosphate binders: effectiveness and safety.
abstract: In patients with kidney dysfunction hyperphosphatemia is more evident as renal failure progresses. It is related to increased FGF-23 levels, secondary hyperparathyroidism, and accelerated progressive vascular calcification. In CKD patients advanced coronary artery calcification is strongly associated with future cardiovascular events, cardiovascular death, and all-cause mortality. Apart from the above, phosphate per se is suspected as a causal risk factor for CKD progression. Keeping serum phosphorus within the target values are linked to improvement in life expectancy. A low phosphate diet, an efficient dialysis removal of phosphate load, and the administration of phosphate binders are the main recommended steps to control hyperphosphatemia. Calcium-based phosphate binders can lead to a positive calcium balance, hypercalcaemia, parathyroid gland suppression, adynamic bone disease, and coronary artery and aortic calcification. On the other hand Sevelamer hydrochloride and Lanthanum carbonate has been shown to be effective, safe and useful therapeutic tools for hyperphosphatemia. When prescribe pharmacological agents, one must take into account the large increase in health-care expenditure and the choice of phosphate binder should be individualized.
authors.affiliation: Department of Internal Medicine, Medical School, University of Ioannina , Ioannina , Greece.
authors.forename: Rigas G
authors.initials: RG
authors.lastname: Kalaitzidis
authors.forename: Moses S
authors.initials: MS
authors.lastname: Elisaf
mesh_terms: D002118:Calcium / Q000097:blood; D002614:Chelating Agents / Q000627:therapeutic use*; D004032:Diet; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood; D006801:Humans; D054559:Hyperphosphatemia / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D006980:Hyperthyroidism / Q000150:complications; D007811:Lanthanum / Q000627:therapeutic use; D010710:Phosphates / Q000097:blood*; D016226:Phosphorus, Dietary / Q000627:therapeutic use; D011073:Polyamines / Q000627:therapeutic use; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications*; D000069603:Sevelamer; D061205:Vascular Calcification / Q000150:complications
chemical_list: D002614:Chelating Agents; C000717427:FGF23 protein, human; D010710:Phosphates; D016226:Phosphorus, Dietary; D011073:Polyamines; C119467:lanthanum carbonate; D005346:Fibroblast Growth Factors; D007811:Lanthanum; D000089703:Fibroblast Growth Factor-23; D000069603:Sevelamer; D002118:Calcium